FDA Panel Rejects Merck’s Gefapixant For Chronic Cough, Calls For Better Endpoints

 
• By Brenda Sandburg
Coughing woman
Evidence does not support use of Merck's gefapixant for treatment of chronic cough, FDA advisory committee concludes • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers